Bioserenity

Executive Summary

Bioserenity is a French digital health company developing an integrated neuroscience platform for remote diagnostics. Founded in 2014 and based in Paris, the company commercializes connected medical devices such as EEG caps and the Neuronaute+ system, enabling at-home or clinical monitoring of EEG and sleep disorders. Its AI-powered software platform facilitates telemedicine by allowing neurologists to analyze and validate exam results remotely, addressing the growing demand for decentralized healthcare solutions. The company operates at the intersection of digital health, diagnostics, and AI, targeting a global neurological diagnostics market valued at over $30 billion. With an aging population and increasing prevalence of sleep disorders and epilepsy, Bioserenity is positioned to capture share through its convenient, cost-effective remote monitoring solutions. While financial details are undisclosed, the company's focus on regulatory clearance and commercial partnerships suggests near-term growth potential.

Upcoming Catalysts (preview)

• Q4 2026CE Marking for Next-Generation Neuronaute+ Device70% success
• Q2 2027Partnership with Major European Sleep Clinic Network60% success
• H1 2027Series B Funding Round75% success